Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (KBLB) has secured patent protection for its recombinant spider silk technologies in the European Union, marking a significant milestone in the commercialization of spider silk. This patent allows the company to exert greater control over its revolutionary materials, with potential applications beyond textiles. The European silk market is projected to reach $2 billion by 2026. The company has also made breakthroughs in developing hydrolyzed spider silk, with details on commercialization expected soon.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the opening of a new spider silk production facility in Vietnam, a significant development in its operations. The custom-built, nearly 10-acre campus includes multiple production and research buildings, along with over 7 acres of mulberry cultivation fields. This site enhances operational efficiency by minimizing logistics costs for feedstock. Despite challenges due to COVID-19 affecting equipment procurement, production has transitioned smoothly, with ongoing expansions of rearing operations to bolster silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the addition of Dr. Jimi Miller as a senior scientist, effective July. His expertise in molecular biophysics and biochemistry is expected to enhance the company’s R&D efforts and commercialization of spider silk fibers. Dr. Miller has already contributed to filing two PCT patent applications and improved screening tools for transgenic development, crucial for large-scale production. The company aims to leverage his skills to innovate in spider silk technology, vital for the textile industry.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the filing of two new patent applications focused on recombinant spider silk technology. These patents utilize advanced gene-editing techniques to enhance protein production systems for more complex silks. The first patent improves silk properties by integrating various mechanical and chemical attributes, while the second extends gene editing capabilities to co-produce complementary proteins for cosmetic and pharmaceutical applications. Both patents are filed under the WIPO Patent Cooperation Treaty, ensuring global protection of the innovations.
Kraig Biocraft Laboratories (KBLB) reported updates on its spider silk production amid COVID-19 restrictions affecting operations in Vietnam. The company has successfully produced silk for various fabric blends in collaboration with PL Kings, but delivery delays are anticipated due to heightened restrictions. Prodigy Textiles has experienced production slowdowns, and egg shipments faced significant delays, resulting in lost inventory. Despite these challenges, KBLB's R&D has advanced, leading to the development of new spider silk strains. The company aims for a national exchange uplisting, but COVID-19 delays are impacting market demand verification.
Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully installed new automated mulberry processing equipment at its Vietnam factory, enhancing spider silk production. This automation can process 300 kg of mulberry leaves per hour, resolving a significant bottleneck in silk manufacturing and ensuring consistent quality. Despite ongoing COVID-related challenges in Vietnam, the team has accomplished this ahead of schedule, marking a pivotal advancement in their production capabilities. This development aims to meet increasing demand for sustainable spider silk fiber.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the transfer of its onsite testing technology to its subsidiary, Prodigy Textiles, in Vietnam. This strategic move aims to enhance production efficiency and facilitate the development of disease-resistant silkworms. By relocating testing and screening operations, the company expects to eliminate delays caused by transporting samples and streamline its production processes. The initiative is part of a broader plan to combat the loss of global silk production, which sees approximately 20% loss due to pathogens.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced significant investments to enhance its production capabilities in Vietnam, focusing on spider silk processing. New automated equipment is set to improve production efficiency at the Prodigy Textiles facility, paving the way for expansion. The facility faced operational challenges due to COVID-19-related shipping restrictions, but with these enhancements, the company aims to mitigate bottlenecks. COO Jon Rice emphasized the importance of building resiliency in production as the company prepares for a post-pandemic environment.
Summary not available.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces significant advancements via its joint venture, Spydasilk Enterprises, with Kings Group. The partnership has applied for four brand trademarks centered on spider silk technology with the US Patent and Trademark Office. These trademarks aim to enhance branding for their yarns and textiles. Additionally, Spydasilk Enterprises plans to expand its distribution network and explore markets beyond apparel, potentially increasing an exclusive agreement valued at up to US$40 million.